IN2012DN05014A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05014A
IN2012DN05014A IN5014DEN2012A IN2012DN05014A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A IN 5014DEN2012 A IN5014DEN2012 A IN 5014DEN2012A IN 2012DN05014 A IN2012DN05014 A IN 2012DN05014A
Authority
IN
India
Prior art keywords
moieties
vegf
ectodomain
antagonize
receptors
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph Schlessinger
Yan Yang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IN2012DN05014A publication Critical patent/IN2012DN05014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
IN5014DEN2012 2009-12-29 2010-12-20 IN2012DN05014A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29078909P 2009-12-29 2009-12-29
PCT/US2010/061296 WO2011090648A2 (en) 2009-12-29 2010-12-20 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2012DN05014A true IN2012DN05014A (de) 2015-10-02

Family

ID=44307462

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5014DEN2012 IN2012DN05014A (de) 2009-12-29 2010-12-20

Country Status (14)

Country Link
US (1) US20130071397A1 (de)
EP (1) EP2519253A4 (de)
JP (1) JP2013515776A (de)
KR (1) KR20120115348A (de)
CN (1) CN102724996A (de)
AU (1) AU2010343193A1 (de)
BR (1) BR112012016309A2 (de)
CA (1) CA2785723A1 (de)
IL (1) IL220147A0 (de)
IN (1) IN2012DN05014A (de)
MX (1) MX2012007745A (de)
RU (1) RU2012132470A (de)
SG (1) SG181495A1 (de)
WO (1) WO2011090648A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155238B1 (de) 2007-06-05 2016-04-06 Yale University Antikörper gegen die d4 domäne des kit rezeptors und anwendungsverfahren
EP3763740A1 (de) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
KR102268351B1 (ko) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 그의 용도
US10188495B2 (en) * 2013-11-01 2019-01-29 Atrium Medical Corporation Positioning agent and method of using the same
EP3145543A4 (de) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Behandlung von eosinophil- oder mastzellenvermittelten erkrankungen
CN104356226B (zh) * 2014-11-04 2017-03-29 青岛海兰深生物科技有限公司 一种检测血浆免疫标志物‑vegfr1自身抗体的抗原多肽及应用
CN108148135B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148136B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11939379B2 (en) 2017-05-19 2024-03-26 The Regents Of The University Of California Antibody chemically induced dimerizer (AbCID) as molecular switches for regulating cellular therapies
CN111183151B (zh) * 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
ES2362931T3 (es) * 2002-03-04 2011-07-15 Imclone Llc Anticuerpos humanos específicos contra kdr y usos de los mismos.
EP2155238B1 (de) * 2007-06-05 2016-04-06 Yale University Antikörper gegen die d4 domäne des kit rezeptors und anwendungsverfahren
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Also Published As

Publication number Publication date
US20130071397A1 (en) 2013-03-21
EP2519253A4 (de) 2013-08-07
EP2519253A2 (de) 2012-11-07
AU2010343193A1 (en) 2012-06-21
JP2013515776A (ja) 2013-05-09
WO2011090648A2 (en) 2011-07-28
SG181495A1 (en) 2012-07-30
WO2011090648A3 (en) 2012-01-05
KR20120115348A (ko) 2012-10-17
IL220147A0 (en) 2012-07-31
BR112012016309A2 (pt) 2017-04-18
CN102724996A (zh) 2012-10-10
RU2012132470A (ru) 2014-02-10
MX2012007745A (es) 2012-11-23
CA2785723A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
IN2012DN05014A (de)
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
MX2011011825A (es) Anticuerpos humanizados para axl.
GB201017345D0 (en) Receptor antagonists
MX2010005031A (es) Anticuerpos de axl.
SMT201600216B (it) Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
EP2271341A4 (de) Spezifische inhibitoren für vaskuläre endothel-wachstumsfaktor-rezeptoren
UA117801C2 (uk) Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру
MX356085B (es) Moduladores novedosos.
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
EP2560684A4 (de) Multimere gerüste auf fibronectin-typ-iii-domänenbasis
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EP2257524A4 (de) N,n-disubstituierte aminoalkylbiphenylverbindungen als antagonisten von prostaglandin-d2-rezeptoren
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
MX2011011127A (es) 3-azabiciclo[4.1.0] heptanos usados como antagonistas de orexina.
IN2012DN00580A (de)
UA106136C2 (uk) 2-піридилзаміщені імідазоли як терапевтичні інгібітори alk5 і/або alk4
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
BRPI0919135A2 (pt) compostos inéditos como ligantes do receptor canabinóide.
TR201903403T4 (tr) İmmünoglobulin preparatı.
WO2012093809A3 (en) New bicyclic compound for modulating g protein-coupled receptors
HK1149003A1 (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists